Amalgamated Bank Has $496,000 Stock Holdings in Certara, Inc. (NASDAQ:CERT)

Amalgamated Bank trimmed its position in shares of Certara, Inc. (NASDAQ:CERT) by 3.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 35,804 shares of the company’s stock after selling 1,130 shares during the quarter. Amalgamated Bank’s holdings in Certara were worth $496,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Mubadala Investment Co PJSC acquired a new stake in shares of Certara during the fourth quarter valued at about $169,135,000. Sei Investments Co. lifted its stake in shares of Certara by 12.4% in the first quarter. Sei Investments Co. now owns 715,514 shares of the company’s stock worth $12,793,000 after acquiring an additional 79,013 shares during the period. Norges Bank acquired a new position in shares of Certara in the fourth quarter worth approximately $14,262,000. Geneva Capital Management LLC lifted its stake in shares of Certara by 15.1% in the first quarter. Geneva Capital Management LLC now owns 4,404,199 shares of the company’s stock worth $78,747,000 after acquiring an additional 579,349 shares during the period. Finally, Wasatch Advisors LP lifted its stake in shares of Certara by 23.4% in the first quarter. Wasatch Advisors LP now owns 4,924,845 shares of the company’s stock worth $88,056,000 after acquiring an additional 932,598 shares during the period. 73.96% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Leif E. Pedersen sold 51,224 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the sale, the insider now owns 99,704 shares in the company, valued at $1,125,658.16. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 2.39% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on CERT shares. Barclays cut their price objective on Certara from $18.00 to $16.00 and set an “equal weight” rating on the stock in a research note on Friday, June 28th. Robert W. Baird cut their price objective on Certara from $19.00 to $18.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. JMP Securities reissued a “market perform” rating on shares of Certara in a research note on Wednesday, July 10th. UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target on the stock in a research note on Friday. Finally, KeyCorp dropped their price target on Certara from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Six research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $17.79.

Certara Trading Up 9.8 %

NASDAQ CERT opened at $11.75 on Monday. The company has a market cap of $1.89 billion, a price-to-earnings ratio of -30.13, a P/E/G ratio of 5.17 and a beta of 1.49. Certara, Inc. has a 52 week low of $10.35 and a 52 week high of $19.87. The business has a 50 day moving average price of $12.73 and a 200-day moving average price of $15.06. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). The firm had revenue of $93.31 million for the quarter, compared to the consensus estimate of $96.01 million. Certara had a negative net margin of 21.64% and a positive return on equity of 3.03%. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.10 EPS. As a group, equities analysts expect that Certara, Inc. will post 0.27 earnings per share for the current fiscal year.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.